Shares of Myovant Sciences MYOV moved higher by 4.5% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share decreased 21.92% over the past year to ($0.89), which beat the estimate of ($0.99).
Revenue of $24,605,000 higher by 0.00% from the same period last year, which missed the estimate of $24,630,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: May 11, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/h7sgwdvh
Recent Stock Performance
52-week high: $30.90
52-week low: $11.55
Price action over last quarter: down 10.29%
Company Description
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.